These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33000229)

  • 1. AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B.
    Takeda T; Tsubaki M; Genno S; Nemoto C; Onishi Y; Yamamoto Y; Imano M; Satou T; Nishida S
    Oncol Rep; 2020 Nov; 44(5):2211-2218. PubMed ID: 33000229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
    Tanaka R; Squires MS; Kimura S; Yokota A; Nagao R; Yamauchi T; Takeuchi M; Yao H; Reule M; Smyth T; Lyons JF; Thompson NT; Ashihara E; Ottmann OG; Maekawa T
    Blood; 2010 Sep; 116(12):2089-95. PubMed ID: 20548094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
    Santo L; Hideshima T; Cirstea D; Bandi M; Nelson EA; Gorgun G; Rodig S; Vallet S; Pozzi S; Patel K; Unitt C; Squires M; Hu Y; Chauhan D; Mahindra A; Munshi NC; Anderson KC; Raje N
    Clin Cancer Res; 2011 May; 17(10):3259-71. PubMed ID: 21430070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.
    Okabe S; Moriyama M; Gotoh A
    Med Oncol; 2024 May; 41(6):142. PubMed ID: 38714583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
    Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
    Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
    Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
    Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
    Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
    Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
    Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
    Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro.
    Shah M; Gallipoli P; Lyons J; Holyoake T; Jørgensen H
    Blood Cells Mol Dis; 2012 Mar; 48(3):199-201. PubMed ID: 22325915
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.
    Illert AL; Seitz AK; Rummelt C; Kreutmair S; Engh RA; Goodstal S; Peschel C; Duyster J; von Bubnoff N
    PLoS One; 2014; 9(11):e112318. PubMed ID: 25426931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.
    Podesta JE; Sugar R; Squires M; Linardopoulos S; Pearson AD; Moore AS
    Leuk Res; 2011 Sep; 35(9):1273-5. PubMed ID: 21665275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells.
    Long ZJ; Wang LX; Zheng FM; Chen JJ; Luo Y; Tu XX; Lin DJ; Lu G; Liu Q
    Int J Oncol; 2015; 46(6):2488-96. PubMed ID: 25872528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.
    Jayanthan A; Cooper TM; Hoeksema KA; Lotfi S; Woldum E; Lewis VA; Narendran A
    Leuk Lymphoma; 2013 Jul; 54(7):1505-16. PubMed ID: 23176524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.
    Mu C; Wu X; Ma H; Tao W; Zhang G; Xia X; Shen J; Mai J; Sun T; Sun X; Arlinghaus RB; Shen H
    Mol Cancer Ther; 2016 May; 15(5):899-910. PubMed ID: 26846820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.